RAPT Therapeutics Statistics
Total Valuation
RAPT has a market cap or net worth of $116.26 million. The enterprise value is -$59.19 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RAPT has 132.29 million shares outstanding. The number of shares has increased by 121.10% in one year.
| Current Share Class | 132.29M |
| Shares Outstanding | 132.29M |
| Shares Change (YoY) | +121.10% |
| Shares Change (QoQ) | +361.39% |
| Owned by Insiders (%) | 0.51% |
| Owned by Institutions (%) | 38.18% |
| Float | 58.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.65 |
| P/TBV Ratio | 0.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.11, with a Debt / Equity ratio of 0.02.
| Current Ratio | 21.11 |
| Quick Ratio | 20.66 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -75.60% and return on invested capital (ROIC) is -48.23%.
| Return on Equity (ROE) | -75.60% |
| Return on Assets (ROA) | -44.72% |
| Return on Invested Capital (ROIC) | -48.23% |
| Return on Capital Employed (ROCE) | -68.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.71M |
| Employee Count | 68 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.70% in the last 52 weeks. The beta is -0.04, so RAPT's price volatility has been lower than the market average.
| Beta (5Y) | -0.04 |
| 52-Week Price Change | -79.70% |
| 50-Day Moving Average | 1.04 |
| 200-Day Moving Average | 1.54 |
| Relative Strength Index (RSI) | 46.80 |
| Average Volume (20 Days) | 867,413 |
Short Selling Information
The latest short interest is 3.58 million, so 2.71% of the outstanding shares have been sold short.
| Short Interest | 3.58M |
| Short Previous Month | 4.00M |
| Short % of Shares Out | 2.71% |
| Short % of Float | 6.10% |
| Short Ratio (days to cover) | 4.53 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -122.85M |
| Pretax Income | -120.43M |
| Net Income | -116.51M |
| EBITDA | -121.71M |
| EBIT | -122.85M |
| Earnings Per Share (EPS) | -$1.37 |
Full Income StatementBalance Sheet
The company has $179.28 million in cash and $3.84 million in debt, giving a net cash position of $175.44 million or $1.33 per share.
| Cash & Cash Equivalents | 179.28M |
| Total Debt | 3.84M |
| Net Cash | 175.44M |
| Net Cash Per Share | $1.33 |
| Equity (Book Value) | 177.37M |
| Book Value Per Share | 1.34 |
| Working Capital | 174.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$108.63 million and capital expenditures -$60,000, giving a free cash flow of -$108.69 million.
| Operating Cash Flow | -108.63M |
| Capital Expenditures | -60,000 |
| Free Cash Flow | -108.69M |
| FCF Per Share | -$0.82 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |